Reuters logo
BRIEF-Biogen reports new data from phase 1b study of investigational Alzheimer's disease treatment Aducanumab
August 28, 2017 / 11:36 AM / 4 months ago

BRIEF-Biogen reports new data from phase 1b study of investigational Alzheimer's disease treatment Aducanumab

Aug 28 (Reuters) - Biogen Inc

* Biogen reports new data from phase 1b study of investigational Alzheimer’s disease treatment Aducanumab

* Biogen Inc- ‍Results support design of ongoing phase 3 studies of Aducanumab for early Alzheimer’s disease​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below